Regorafenib After Lenvatinib Failure in Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer (HCC) whose disease got worse or stopped tolerating lenvatinib, an earlier treatment. The goal is to see if switching to regorafenib can slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of hepatocellular carcinoma (HCC), a type of liver cancer
- Your HCC cannot be surgically removed and got worse or caused intolerable side effects on lenvatinib treatment
- At least one measurable tumor spot visible on imaging (RECIST v1.1 criteria)
- Liver function in Child-Pugh class A or B7 range (mild-to-moderate liver damage, not severe)
- Blood counts and kidney/liver function within acceptable ranges (checked within 14 days before enrollment)
- No severe heart disease, recent heart attack, or stroke in the last 3 months; no active brain tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regorafenib, a targeted cancer drug, can help patients with advanced liver cancer whose disease progressed after or couldn't tolerate first-line immunotherapy. The goal is to see if this drug can slow or shrink the cancer.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
This trial tests lenvatinib, a targeted therapy, as the first treatment for people with hepatocellular carcinoma (HCC, a type of liver cancer) who have moderate liver damage (Child-Pugh B7-B8) and cannot have surgery or other local treatments. The goal is to see if it helps control the cancer.
Hear when a new Lenvatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.